ChromaDex Corp. was established to become the market leader in the creation and supply of botanical reference standards along with related phytochemical products and services. Due to the need for reference standards and other quality assurance methods to identify active substances, drug/compound interactions, and the presence of toxic or adulterating materials, ChromaDex™ provides the tools necessary to help with the quality and control of the market. Listed on the OTC Bulletin Board, ChromaDex Corporation has their headquarters in Irvine, California.

The Company’s primary focus is to create industry-accepted information, products, and services to every layer of the functional food, pharmaceutical, personal care, and dietary supplement markets. They offer the most extensive phytochemical catalog in the world. ChromaDex provides a broad range of analytical services, contract isolation, microbiological, process development, bioassay services, and consulting. These all center on their expertise in natural products. They provide a wide range of services to food, beverage, cosmetic, dietary supplement, and pharmaceutical companies looking for expertise in natural products based services.

ChromaDex is currently focusing on clinical studies and the commercialization of their new product, pTeroPure™ pterostilbene. They received an exclusive worldwide license to all patent rights of pterostilbene from the University of Mississippi and the Agricultural Research Service. The term of the license is up to and including the expiration of various pterostilbene patents held by the licensors.

Pterostilbene has a chemical relation to Resveratrol, a compound found in grapes, blueberries, other small fruits, and the bark of some trees. It is believed that Resveratrol is at least partly responsible for the health benefits attributed to drinking red wine, which include cardiovascular health and cancer prevention.

In September 2010, ChromaDex announced that they initiated a clinical study at The University of Mississippi for pTeroPure™ pterostilbene. The next generation novel ingredient is based on the grant of an exclusive worldwide license to all patent rights of pterostilbene from the University of Mississippi. The clinical trial is being conducted at the UM Medical Center in Jackson, where investigators hope to evaluate the compound in patients with lipid (cholesterol) disorders.

In laboratory tests, pterostilbene has shown promise for improving cardiovascular health, glucose levels, anti-ageing and cognitive function; as well as for possessing cancer-fighting properties. Various scientific publications have shown that pterostilbene has significantly higher activity than resveratrol.

Yesterday, ChromaDex and Bruker Optics Inc., a subsidiary of Bruker Corporation (BRKR), announced a co-development and co-marketing agreement. This agreement will promote a new approach to dietary supplement testing. Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analysis.

The collaboration will capitalize on the extensive phytochemical and botanical reference standard capabilities of ChromaDex. It will focus initially on the near infrared spectrometer (NIR) technology created by Bruker Optics. The parties anticipate extending the relationship to include other Bruker analytical technologies. Through this collaboration, a dietary supplement producer will have the opportunity to obtain the in-house capabilities of a contract laboratory without the associated start-up costs.